Biotech
Evelo Biosciences
Evelo Biosciences raises $75M Series D at $500M valuation
$75M
Total Raised
Series D
Latest Round
2014
Founded
150+
Employees
620 Memorial Drive, Cambridge, MA 02139
1 min read
Quick Facts
Valuation
$500M
Latest Round Size
$75M
Latest Round Date
August 2024
Evelo Biosciences: Series D Funding Round
Evelo Biosciences has successfully raised $75M in Series D funding, reaching a valuation of $500M.
Company Overview
Monoclonal microbials for cancer and inflammation
Funding Details
The Series D round was led by Fidelity, with participation from Celgene, Kaiser Permanente Ventures, Flagship Pioneering.
Company Information
- Headquarters: 620 Memorial Drive, Cambridge, MA 02139
- Founded: 2014
- Employees: 150+
- Category: Biotech
Investment
Evelo Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Celgene: Verified investor in Series D
- Kaiser Permanente Ventures: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Key Investors
Fidelity
Lead Investor
Verified investor in Series D
Celgene
Investor
Verified investor in Series D
Kaiser Permanente Ventures
Investor
Verified investor in Series D
Flagship Pioneering
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M